Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

Mistry, Pramod K; Balwani, Manisha; Baris, Hagit N; Turkia, Hadhami Ben; Burrow, T Andrew; Charrow, Joel; Cox, Gerald F; Danda, Sumita; Dragosky, Marta; Drelichman, Guillermo; El-Beshlawy, Amal; Fraga, Cristina; Freisens, Selena; Gaemers, Sebastiaan; Hadjiev, Evgueniy; Kishnani, Priya S; Lukina, Elena; Maison-Blanche, Pierre; Martins, Ana Maria; Pastores, Gregory; Petakov, Milan; Peterschmitt, M Judith; Rosenbaum, Hanna; Rosenbloom, Barry; Underhill, Lisa H; Cox, Timothy M.
Blood Cells Mol Dis; 77: 101-102, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31029022